P

Pfizer

Makes cancer drugs, vaccines and other medicines

Key Account Manager Rare Disease

Full-TimePosted on 10/19/2026Deadline 10/24/26
$176.6k - $294.3k/yr
Mid
Bachelor's, Master's, MBA
Mississippi, USA+3 moreMore locations: Arkansas, USA | Oklahoma, USA | Louisiana, USA
RemoteRemote within Arkansas, Oklahoma, Louisiana, or Mississippi; candidate is expected to live in the role's geographic area.
Sales & Account ManagementAccount Management
No H1B Sponsorship

About the job

Requirements
  • Management and/or Account Management experience is strongly recommended.
  • A Bachelor's degree is required; an MBA or advanced degree in a related field is preferred.
  • Five to ten years of previous pharmaceutical, biotech, or medical marketing/sales experience is preferred, with at least three years in a promoted position and/or developmental role demonstrating leadership across peer and manager groups.
  • Rare Disease and/or Specialty Cardiovascular experience and expertise are strongly preferred.
  • Product launch experience is preferred.
  • Prior team management is preferred.
  • The candidate is expected to live in the geographic area of the role.
  • Demonstrated knowledge of the healthcare market and Rare Disease therapeutic category disease states.
  • Ability to develop and manage relationships with Key Accounts, including C-suite leaders and key opinion leaders.
  • Demonstrated account management and negotiation skills, and ability to prioritize resources and develop business plans.
  • Ability to understand, influence, and adapt to changing local healthcare, customer, and stakeholder needs.
  • Ability to assess and prioritize an account portfolio and allocate limited resources to create wins for customers and Pfizer.
  • Ability to align local, regional, or national account needs with Pfizer goals, understand healthcare and local market trends, and develop appropriate account plans.
  • Strategic planning, critical and analytical thinking, and execution and measurement of outcomes.
  • Ability to build and maintain trusting relationships, communicate persuasively in writing and orally, listen effectively, and tailor communication to the audience.
  • Networking, stakeholder management, and influencing without authority.
  • Ability to uphold Pfizer values, provide a vision for delivering Pfizer Innovative Health goals, and, where applicable, support people development, coaching, and performance management.
  • Ability to adapt positively to new challenges and ambiguity, stay focused on performance, and coach others through change.
  • Self-awareness and commitment to compliance.
  • Must be authorized to work in the United States by any employer and have permanent work authorization in the United States.
Responsibilities
  • Develop market insights and understand influencers in Rare Disease therapeutic categories and accounts/customers.
  • Manage accounts and develop relationships with C-suite, administrative, and Rare Disease therapeutic service-line leaders.
  • Develop and implement account plans for assigned accounts and identify, develop, and advance potential partnership opportunities between Pfizer and accounts/customers.
  • Work with Pfizer stakeholders to identify and develop appropriate Rare Disease Key Account Manager opportunities.
  • Work with state, regional, or district business leaders and cross-functional Pfizer specialists to ensure appropriate account support.
  • Segment and prioritize accounts and identify key customers within them, including integrated delivery networks, integrated delivery systems, accountable care organizations, medical groups, independent physician associations, professional societies, healthcare provider organizations, quality improvement organizations, and IDN specialty pharmacies within the defined distribution network.
  • Identify key customers and the decision-making and influencing network within accounts and local health economies.
  • Maintain effective relationships with key customer C-suite leaders, Rare Disease therapeutic service-line leaders, administrative contacts, and decision-makers in prioritized accounts.
  • Develop effective relationships with key opinion leaders and stakeholders in local health economies.
  • Understand and seek to influence local, regional, and national healthcare issues and best practices aligned with markets and key accounts; political and advocacy organization engagements are led by Political Affairs colleagues.
  • Manage co-execution of project plans and hold customers and Pfizer accountable for execution.
  • Manage prioritized accounts to achieve agreed business objectives.
  • Identify opportunities for synergy and collaboration through active and transparent customer and account planning.
  • Analyze local environments, account business, and Pfizer priorities to create account plans identifying mutually beneficial opportunities.
  • Leverage Rare Disease value propositions to create actionable, mutually beneficial business opportunities.
  • Connect and communicate insights from multiple stakeholders to develop mutually beneficial plans of action.
  • Partner with the Rare Disease IAT to help colleagues understand local market and customer drivers.
  • Influence development of Key Account Manager efforts locally, regionally, or nationally by partnering with cross-functional teams to shape compliant efforts and deliver results.
  • Share and scale proven practices across the region and nation.
  • Lead and support development of a high-functioning cross-functional team across sales, medical, marketing, HIT, and IM KAM, consistent with the account team model.
  • Develop expertise in healthcare reform, the evolving landscape, and the organization of accounts and customers.
  • Lead development of Rare Disease account and strategic planning priorities.
  • Apply Rare Disease therapeutic category and healthcare market knowledge to understand factors influencing IDN behavior, and engage appropriate colleagues from other functional areas to build and execute strategic plans addressing issues or solving problems.
  • Use organizational awareness and align Pfizer priorities to involve appropriate colleagues with accounts and optimize value for customers and Pfizer.
  • Lead pull-through activities aligned with Pfizer business leader direction.
  • Coordinate effectively with cross-functional teams.
  • Communicate short-, mid-, and long-term Pfizer business perspectives to key accounts and deliver ongoing Rare Disease portfolio opportunities, aligning across Pfizer business units when appropriate.
  • Provide regional marketing and strategy teams with local and customer-specific insights for developing market-specific materials.
Desired Qualifications
  • MBA or advanced degree in a related field.
  • Five to ten years of previous pharmaceutical, biotech, or medical marketing/sales experience, including at least three years in a promoted position and/or developmental role demonstrating leadership across peer and manager groups.
  • Rare Disease and/or Specialty Cardiovascular experience and expertise.
  • Product launch experience.
  • Prior team management.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.